Salarius Pharmaceuticals (NASDAQ: SLRX)
FY 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-12-20 | ||||||
REV |
FY 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-11-09 | ||||||
REV |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Salarius Pharmaceuticals (NASDAQ: SLRX) through any online brokerage.
Other companies in Salarius Pharmaceuticals’s space includes: Allena Pharma (NASDAQ:ALNA), Immuron (NASDAQ:IMRN), Midatech Pharma (NASDAQ:MTP), Cyclacel Pharmaceuticals (NASDAQ:CYCC) and Biophytis (NASDAQ:BPTS).
The latest price target for Salarius Pharmaceuticals (NASDAQ: SLRX) was reported by Cantor Fitzgerald on Friday, August 12, 2022. The analyst firm set a price target for 4.00 expecting SLRX to rise to within 12 months (a possible 1580.67% upside). 50 analyst firms have reported ratings in the last year.
The stock price for Salarius Pharmaceuticals (NASDAQ: SLRX) is $0.238 last updated August 12, 2022, 8:00 PM UTC.
The next Salarius Pharmaceuticals (SLRX) dividend date is projected to be Thursday, September 1, 2022.
Salarius Pharmaceuticals’s FY earnings are confirmed for Wednesday, December 20, 2023.
There is no upcoming split for Salarius Pharmaceuticals.
Salarius Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.